Announcements Trials
Browse Landscape

Phase

Phase 1 69Phase 2 49Phase 1/2 29Phase NA 25Phase 3 10Phase EARLY_PHASE1 6Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 10Thoracic 2Gastrointestinal 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 26Uterine Cervical Neoplasms 16Endometrial Neoplasms 14Fallopian Tube Neoplasms 10Carcinoma, Ovarian Epithelial 7Colorectal Neoplasms 6Peritoneal Neoplasms 5Neoplasms 5Uterine Cervical Dysplasia 4Lung Neoplasms 4Gestational Trophoblastic Disease 4Pancreatic Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3Melanoma 3Hematologic Neoplasms 3Endometrial Hyperplasia 3Urinary Bladder Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2Prostatic Neoplasms 2Progesterone Resistance 2Ovarian Cysts 2Obesity 2Multiple Myeloma 2Lymphoproliferative Disorders 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Glioma 2

Interventions

Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Sarcoma × Gynecologic × Clear all
NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Pierian Biosciences

Phase 2/3 Completed
150 enrolled
BreastGynecologicSarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡